Shorter individuals twice as likely to develop esophageal cancer
the ONA take:
According to a new study published in the journal Clinical Gastroenterology and Hepatology, researchers at Fred Hutchinson Cancer Research Center in Seattle, Washington, have found that taller individuals are less likely to develop Barrett's esophagus and esophageal cancer than shorter individuals.
For the study, the researchers analyzed data from 14 studies within the International Barrett's and Esophageal Adenocarcinoma Consortium (BEACON). They found that those in the lowest quartile of height, or men under 5'7" and women under 5'2", were approximately twice as likely as those in the highest quartile of height, or men taller than 6' and women taller than 5'5", to have esophageal cancer or Barrett's esophagus.
Bases on analyses, results were consistent among various other factors, including age, body mass index, education, gastroesophageal reflux disease (GERD) symptoms, sex, and smoking. Researchers suggest that height may be able to be used as a risk factors to identify patients with a higher risk of developing Barrett's esophagus or esophageal cancer. Of note, the relationship between height and esophageal cancer observed in this study is the opposite of what has been observed in breast, colorectal, and prostate cancers.
Taller individuals are less likely to develop Barrett's esophagus and esophageal cancer.
A new study has observed that tall people are less likely to suffer from esophageal cancer as compared to short people.
The study conducted a large pooled analysis using data from 14 population-based epidemiologic studies within the International Barrett's and Esophageal Adenocarcinoma Consortium (BEACON), including 1,000 cases of esophageal cancer and twice as many cases of Barrett's esophagus, and twice as many controls.
Sign Up for Free e-newsletters
- Hodgkin Lymphoma Survivorship Marked by Periods of Actionable Distress
- Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis
- Stem Cell Transplantation Superior to Chemotherapy for Relapsed/Refractory DLBCL, Follicular Lymphoma
- Patients and Caregivers Worry About Cost of Cancer Care
- Integrative Medicine in Childhood Cancer: Practices That Can Help Pediatric Patients
- Navigating Prostate Cancer: A Patient's Experience From Diagnosis to Survivor
- Cell Phones and Cancer Risk (Fact Sheet)
- How Likely Are Oncologists to Refer for Palliative Care? Depends on Their Age
- Chemoimmunotherapy Increases Survival in Triple-Negative Breast Cancer
- Seeking an Explanation for the Lack of Research Focused in Pediatric Oncology Therapeutics
- Risk for Colon Cancer, Osteogenic Sarcoma Higher With Presence of Diamond-Blackfan Anemia
- G-CSF Support Increases Overall Survival, But Risk of Secondary Malignancies Also Higher
- Report From Childhood Cancer Survivor Study Identifies Long-Term Risks for VTE
- The Effect of Intravenous Hydration Strategy on Plasma Methotrexate Clearance During Intravenous High-dose Methotrexate Administration in Pediatric Oncology Patients
- Outcomes Worse for Minimally Invasive Hysterectomy vs Open Surgery
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|